Evidence-Based Reviews

Negative symptoms of schizophrenia: An update

Current Psychiatry. 2020 October;19(10):24-25,30-33,53 | doi:10.12788/cp.0049

References

1. Owen MJ, Sawa A, Mortensen PD. Schizophrenia. Lancet. 2016;388(10039):86-97.
2. Cerviri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525-1535.
3. Mitra S, Mahintamani T, Kavoor AR, et al. Negative symptoms in schizophrenia. Ind Psychiatr J. 2016;25(2):135-144.
4. Fusa-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892-899.
5. Remington G, Foussias G, Fervaha G, et al. Treating negative symptoms: an update. Curr Treat Options Psych. 2016;3:133-150.
6. Harvey PD, Saoud JB, Luthringer R, et al. Effects of roluperidone (MIN-101) on two dimensions of negative symptoms factor score: reduced emotional experience and reduced emotional expression. Schizophr Res. 2020;215:352-356.
7. Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Psychopharmacol Exp Ther. 2019;371(1):1-14.
8. Bleuler E. Dementia praecox or the group of schizophrenia. New York, New York: International Universities Press; 1950.
9. Andreasen NC. The diagnosis of schizophrenia. Schizophr Bull. 1987;13(1):9-22.
10. Andreasen NC. Thought, language, and communication disorders I. Clinical assessment, definition of terms, and evaluation of their reliability. Arch Gen Psychiatry. 1979;36(12):1315-1321.
11. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 1980;280(6207):66-68.
12. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry. 1982;39(7):789-794.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
14. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300-305.
15. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptoms Assessment. J Psychiatr Res. 1993;27(3):253-258.
16. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578-583.
17. Bobes J, Arango C, Garcia-Garcia M, et al. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS Study. J Clin Psychiatry. 2010;71(3):280-286.
18. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
19. Black DW, Andreasen NC. Interviewing and assessment. In: Introductory textbook of psychiatry, 7th ed. Black DW, Andreasen NC, eds. Washington, DC: American Psychiatric Publishing; 2020:15-53.
20. Pfohl B, Winokur G. The micropsychopathology of hebephrenic/catatonic schizophrenia. J Nerv Ment Dis. 1983;171(5):296-300.
21. Hovington CL, Lepage M. Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother. 2012;12(1):53-69.
22. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al. A review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull. 2006;70(4-6):312-321.
23. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep. 2007;9(4):329-336.
24. Yoshimura R, Hori H, Katsuki A, et al. Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF, and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia. Ann Gen Psychiatry. 2016;15:1.
25. Moller HJ. Management of negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17(11):793-823.
26. Leucht S. Amisulpride: a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2004;7(suppl 1):S15-S20. doi: 10.1017/S1461145704004109.
27. Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomized, double-blind, controlled trial. Lancet. 2017;389(10074):1103-1113.
28. Neill JC, Grayson, Kiss B, et al. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016;26(1):3-14.
29. Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876-886.

Negative symptoms of schizophrenia: An update

References

Related Resources

Drug Brand Names

Pages

Recommended Reading